Urnovitz HB, Murphy WH. Human endogenous retroviruses: Nature, occurrence and clinical implications in human disease. Clinical Microbiology Reviews 1996; 9:72–99.
Urnovitz HB, Murphy WH, Gottfried TD, and Friedman-Kien, AE. Urine-based diagnostic technologies. Trends in Biotechnology 1996; 14:361–364.
Ventura SJ, Martin JA, Mathews TJ, et al. Advance report of final natality statistics, 1994. Monthly vital statistics report; 44(11) Suppl. Hyattsville, Md.: National Center for Health Statistics, 1996.
Vergelli M, Hemmer B, Utz U, et al. Differential activation of human autoreactive T-cell clones by altered peptide ligands derived from myelin basic protein peptide (87–99). European Journal of Immunology 1996; 26:2624–2634.
Vogt AB, Kropshofer H, Kalbacher H, et al. Ligand motifs of HLS-DRB5 *0101 and DRBI*1501 molecules delineated from self-peptides. Journal of Experimental Medicine 1994; 153:1665–1673.
Waisbren BA. Other side of the coin (letter). Infectious Disease News 1992; 5:2.
Warkany J. Congenital Anomalies: Notes and Comments. Chicago: Year Book Medical Publishers , 1971.
Westall FC, Root-Bernstein RS. An explanation of prevention and suppression of experimental allergic encephalomyelitis. Molecular Immunology 1983; 20:169–177.
White CS, Adler WH, McGann VG. Repeated immunization: Possible adverse effects. Reevaluation of human subjects at 25 years. Annals of Internal Medicine 1974; 81:594–600.
Wucherpfennig KW, Wette A, Southwood S, et al. Structural requirements for the binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T-cell clones. Journal of Experimental Medicine 1994; 179;279–290.
Zhang J, Markovic S, Lacet B, et al. Increased frequency of IL2 responsive T-cells specific for myelin basic protein and preteolipid protein in peripheral blood and cerebrospinal fluid of patients with Multiple sclerosis. Journal of Experimental Medicine 1994; 179:973–984.